Drugs / LUT017
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07463365 | Oct 2026 → Feb 2027 expected | ulcer of lower limbs | Antoni Ribas | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07463378 | Apr → Oct 2026 expected | — | Antoni Ribas | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUT017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07463378 ↗ |
| Action | Inhibit | “LUT017 is a small-molecule inhibitor of BRAF.” NCT07463365 ↗ |
| Modality | Small molecule | “LUT017 is a small-molecule inhibitor of BRAF.” NCT07463378 ↗ |
| Route | Topical | “single-dose topical administration” NCT07463378 ↗ |
| Target | BRAF | “LUT017 is a small-molecule inhibitor of BRAF.” NCT07463365 ↗ |